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Prognostic Value of Fluorodeoxyglucose Positron Emission
Tomography in Non-small Cell Lung Cancer: A Review
Giancarlo Pillot, MD,* Barry A. Siegel, MD,†‡ and Ramaswamy Govindan, MD*‡
Abstract: Non-small cell lung cancer (NSCLC) remains a leading
cause of cancer morbidity and mortality. Adjuvant chemotherapy
improves survival in resected early-stage NSCLC. However, a
significant proportion of patients with early-stage lung cancer are
cured by surgery alone. There are no reliable clinical or molecular
markers to predict outcomes after surgery in early-stage NSCLC.
Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glu-
cose (FDG-PET) improves the accuracy of staging work-up in
NSCLC. The standardized uptake value, a commonly used semi-
quantitative measure of FDG uptake, correlates with tumor doubling
time and indices of cell cycling. Therefore, FDG-PET may be a
useful predictor of outcome independent of its role in tumor staging.
In this review, we critically examine the published studies on the
utility of FDG-PET as a prognostic tool in patients with NSCLC and
provide direction for future research.
Key Words: Non-small cell lung cancer, 2-[18F]fluoro-2-deoxy-D-
glucose positron emission tomography, Prognosis.
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Lung cancer is the leading cause of cancer-related death inboth men and women in the United States, with an
estimated 172,570 new cases and 163,510 patients dying
from this disease in 2005.1 More than 87% of patients with
lung cancer are diagnosed with non-small cell lung cancer
(NSCLC); of these, approximately 30% will present with
resectable disease.2,3 It has now become an accepted practice
to offer adjuvant chemotherapy for patients with resected
stage IB and II NSCLC based on the results of several
prospective studies that have demonstrated a statistically and
clinically significant survival advantage with this ap-
proach.4–6 However, these studies have also demonstrated
that nearly 60% of patients with resected stage IB NSCLC
and 45% of patients with stage II NSCLC will not have
recurrent disease after resection even without adjuvant ther-
apy. Unfortunately there are no reliable clinical, radiological,
or molecular predictive markers to identify those patients at
high risk of recurrent disease.
A number of factors other than tumor stage have been
shown to have prognostic significance in patients with re-
sected NSCLC.7,8 However, the available data from retro-
spective studies are hard to interpret as they are derived from
a mixed group of patients with differing stages of disease who
undergo various treatments. Specifically, among patients with
stage I disease, clinical and pathologic features such as tumor
size,9 extent of surgery,10 and factors such as visceral pleural
invasion or high mitotic rate11 have demonstrated some
correlation with prognosis. Other biological markers, such as
Ki-67 labeling index12 (a cell proliferation marker), p53
mutation status,13 bcl-2 expression,14 and gene expression
profiling,15,16 have also provided correlative information.
However, the published studies have not yielded consistent
results for all markers17 and have been often hampered by
small sample size. Moreover, many individual markers lose
their unique prognostic significance when they are subjected
to multivariate analysis.18 Although these molecular ap-
proaches hold promise for prognostic risk stratification of
patients with early-stage NSCLC, none has yet been validated
prospectively. Additionally, the need for further testing of
original tumor tissue would add further expense, as well as a
clinical delay while awaiting the results. An easy-to-use,
readily available clinical variable or set of variables thus may
be more useful and more quickly incorporated into practice
both in academic centers and in the community.
Positron emission tomography (PET) with the glucose
analogue 2-[18F]fluoro-2-deoxy-D-glucose (FDG) is a useful
imaging method for diagnosing, staging, and monitoring
therapy of several malignancies.19,20 FDG-PET enhances the
accuracy of clinical staging and excludes patients with distant
metastasis or advanced nodal disease from futile surgery.21–23
Although most studies of FDG-PET in NSCLC have focused
on its use in staging, the intensity of FDG uptake in an
individual tumor also may serve as a surrogate marker of the
biological behavior of that tumor. The purpose of this study
was to review the role of the semiquantitative assessment of
tumor FDG uptake as a prognostic indicator for NSCLC.
Background
The interested reader is referred to other reviews of the
methodology for FDG-PET.19 Briefly, FDG-PET is per-
formed by the injection of FDG, a radiopharmaceutical that is
taken up by most cancer cells to a greater extent than by most
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normal cells. Intracellularly, FDG is phosphorylated in a
manner similar to glucose; however, the resultant FDG-6-
phosphate is not further metabolized and is retained (“meta-
bolically trapped”) in the cell. When the F-18 radionuclide
decays, the resulting annihilation photons are detected by the
PET scanner; the data from many detected decay events are
transformed into a three-dimensional representation of signal
intensity. Areas in the body that produce significant signal as
a result of increased FDG uptake are visible on FDG-PET
images. However, this signal is attenuated by body tissues,
which absorb or scatter the annihilation photons as they pass
through the patient. Correction of the emission data for
attenuation is performed with a separate transmission scan.
This can be obtained either with an extrinsic radiation source
(such as germanium- 68), as is typically done in a conven-
tional PET scanner, or with X-rays, as is done with the
computed tomographic (CT) component of the study from a
dedicated PET/CT scanner. However, these different methods
of attenuation correction can also contribute to differences in
the perceived PET signal.24
Although tumor FDG uptake can be quantified by
several different methods,25 the one most commonly used in
clinical practice is the standardized uptake value (SUV).26
The SUV is defined as:
Suv  CROI/(A/Wt)
where CROI is the decay-corrected tracer concentration in
Ci/cm3 measured on the PET image within a region of
interest (ROI); A is the total injected activity of the radio-
pharmaceutical in Ci; and Wt is the patient’s body weight
in grams. The denominator of this equation (A/Wt) is the
average concentration of the tracer within the body (assuming
that there has been no elimination of the tracer). The SUV for
any ROI can be either the mean value within the region
(SUVmean) or the value for the voxel within the region having
the maximal signal (SUVmax). The SUVmean is highly depen-
dent on the method used for ROI placement. The ROI is
drawn around a lesion that may not be sharply demarcated,
portions of which may include an admixture of tumor and
normal tissue that cannot be distinguished because of the
limited resolution of the PET scanner; inclusion of this lower
activity tissue in the ROI will artificially decrease the mea-
sured signal. Additionally, the SUVmean reflects the variabil-
ity in tracer uptake from one region to another within the
tumor, including areas with low activity as a result of poor
blood supply or necrosis. The SUVmax, as the result for a
single pixel, is subject to greater statistical variability because
of the noise in the reconstructed PET image. With small
lesions, both measures will be reduced by the effects of
partial volume averaging, the error introduced when the
lesion size is less than twice the spatial resolution of the
scanner.27
The SUV has a number of other limitations as a
measure of tracer uptake in a tumor28 and can be affected by
several factors not specifically related to the intrinsic meta-
bolic activity of the tumor (Table 1). One important factor in
the variability of SUV is the interval from the injection of
FDG to imaging. Although imaging was initiated 40-60
minutes after injection of FDG in most of the studies that we
review herein, the tumor uptake of the tracer is still increasing
at this time, and the plateau of uptake does not typically occur
for several hours. In one series of patients with untreated
NSCLC, the 60-minute SUV was 46% lower than the value
measured at the plateau of the uptake phase.29 The plasma
glucose level during the period of FDG uptake can also affect
the SUV because glucose competes with FDG for uptake into
cancer cells. Insulin levels are also important because insulin
increases FDG uptake in skeletal muscle and adipose tissue,
making less FDG available for uptake in the tumor; this is
why oncological FDG-PET studies are performed after 4 or
more hours of fasting. The SUV is also affected by body
habitus.26 Because of the relatively low uptake of FDG in
adipose tissue, the apparent SUVs of tumors (and of other
tissues) will be higher in obese patients than in those of
normal body weight. To address this problem, it has been
suggested that the SUV should be normalized to the patient’s
lean body mass or body surface area.30 Physical effects
related to scan acquisition also affect the SUV. Because data
acquisitions for PET typically take several minutes at each
scanner position, the respiratory motion of lung tumors is an
additional basis for partial volume averaging; again, this
effect is greatest with small tumors. With PET/CT, this
respiratory variation of tumor location has been demonstrated
to produce additional variability in SUV of up to 30%,
because of respiratory misregistration of the CT and PET
data sets, which results in incorrect attenuation correction
of the emission PET data.24 Finally, the method of image
reconstruction affects SUV, with certain methods of re-
construction leading to underestimates of SUV by up to
30%.31 Accordingly, SUVs determined with different
scanners, acquisition protocols, and reconstruction
methods may not be comparable.
Despite all these challenges, the SUV can be used as a
reasonably reliable semiquantitative measurement of tumor
uptake. Variability in uptake related to fasting blood glucose
level, time from FDG injection to imaging, and method of
SUV determination can be standardized. SUVmax normalized
to lean body mass has been shown to be reproducible in
patients with lung cancer across repeat determinations; re-
peated values were within a mean of 11.3% of each other.32
It should be noted, however, that this reproducibility was only
tested in tumors larger than 2 cm in size.
TABLE 1. Factors Affecting SUV Determination
Blood glucose level at time of FDG injection
Plasma insulin level at time of FDG injection
Body habitus
Time of image acquisition after injection of FDG
Lesion characteristics
Size/ partial volume effects
ROI placement
Respiratory variation of position of lesion of interest
Method of image reconstruction and attenuation correction
SUV, standardized uptake value; FDG, 2-[18F]fluoro-2-deoxy-D-glucose; ROI,
region of interest.
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Biological Correlates of FDG-PET Signal
Intensity
The results of FDG-PET have been correlated with
several presumed markers of tumor aggressiveness. In one
study33 of patients referred to Duke University for FDG-PET
evaluation of indeterminate focal pulmonary abnormalities,
serial chest radiographs or CT scans were assessed for dou-
bling time of the lesion of interest and correlated with the
SUVmean. In this study, an SUVmean more than or equal to 2.5
was found in 49 of 53 lesions proved to be malignant.
Additionally, the SUVmean was found to correlate with lesion
doubling time. The SUV for FDG has also been shown to
correlate with lung cancer proliferation as measured by indi-
ces of cell proliferation. Higashi et al.34 demonstrated a
correlation between SUV (measured within a ROI encom-
passing all pixels with activity 90% of the maximal pixel
activity in the primary tumor) and tumor cell proliferation of
subsequently resected samples as measured by proliferating
cell nuclear antigen labeling. These investigators found a
much weaker correlation between tumor cell density and
SUV and reported that brochioalveolar carcinomas tended to
have lower SUVs than other histological types of NSCLC.
Vesselle et al.35 also studied the correlation of FDG uptake
with tumor proliferation in a series of patients, most of whom
went on to surgical resection (35 of 39 study patients). They
found a positive correlation between SUVmax and tumor cell
proliferation as measured by Ki-67 labeling, with the corre-
lation being most robust in patients with stage I NSCLC.
They also noted an association between degree of cellular
differentiation as determined by pathologic grading by light
microscopy and SUV max. In another study of pulmonary
adenocarcinomas, Higashi et al.36 also demonstrated a corre-
lation between SUV for FDG (measured within a ROI en-
compassing all pixels with activity 80% of the maximal
pixel activity in the primary tumor) and perceived indices of
aggressiveness, such as pleural involvement, vascular inva-
sion, or lymphatic invasion. It should be noted, however, that
PET scanning with another radiopharmaceutical, 3= deoxy-
3=-18F-fluorothymidine may be better correlated with tumor
proliferation (as assessed by Ki-67 staining) than FDG.37
In aggregate, these data demonstrate that the SUV
measured by FDG-PET correlates with several indices of
tumor growth and aggressiveness. It is a reasonable postulate,
therefore, that SUV may also be associated with outcome.
Summary of Published Reports Correlating
SUV with Patient Outcome
Ten published studies from several countries have cor-
related prognosis with SUV in NSCLC. All have been single-
institution, retrospective studies. One of these studies failed
to demonstrate that SUV correlated with prognosis, whereas
the remaining nine demonstrated a statistically significant
result. Tables 2 and 3 summarize the technical aspects of scan
acquisition, patient populations investigated, and results of
these studies.
In a study of FDG-PET in mediastinal staging of
NSCLC at the University of Michigan,38 SUVmax of the
primary tumor was measured and compared with outcome.
Of a total of 97 identified patients who underwent FDG-PET,
38 met enrollment criteria of histologically proven NSCLC
that had been previously untreated. Patients who died of
non-cancer causes or were lost to follow-up were excluded.
Approximately 31% of these patients had early-stage (I or II)
disease, and the median follow-up period was 26.5 months.
These investigators chose the median SUV of their patient
population (8.72) as the cutoff to discriminate between high-
and low-uptake groups. These investigators found no statis-
tically significant difference between the survival of patients
in the high- and low-uptake groups. They did, however, note
a nonsignificant trend toward better survival in patients with
SUVmax less than or equal to 8.72 who also were free of N2
or M1 disease. This study is limited by its small size and by
the broad ranges of both stage and histological subtype
among the patients evaluated; therefore, few conclusions can
be drawn from its failure to demonstrate a statistically sig-
nificant association between SUV and stage. The squamous
cell carcinomas had a higher SUV than the adenocarcinomas,
although it is not clear whether this SUV difference correlates
with tumor size.
Vansteenkiste et al.39 analyzed the outcome of Belgian
patients assessed by FDG-PET who had been enrolled in
protocols investigating lymph node staging and the evalua-
tion of solitary pulmonary nodules. They analyzed the course
of 125 patients, almost all of whom were surgically staged.
The mean follow-up time of patients in this study was 19
months. When more than one lesion was noted on PET, the
SUVmax of the primary tumor was used. In this study,
approximately half of the patients had early-stage (I or II)
disease, and most of these were treated with surgery alone.
The authors chose a SUVmax cutoff value of 7 by testing
several different cutoffs for statistical significance and using
the value with the greatest statistical significance. They did
find a continuum of statistically significant cutoffs between
SUV values of 6 and 11. In addition to finding that survival
was related to performance status, stage, and tumor histology,
they demonstrated a statistically significant difference in
survival among patients based on SUVmax. In a subgroup
analysis of patients of all stages who were treated with
surgery at some point in their clinical course, the survival
difference based on SUVmax persisted. In a multivariate
analysis, stage, performance status, and SUVmax were inde-
pendent prognostic variables.
Investigators at Duke University also reviewed the
prognostic significance of SUV.40 They reviewed all 155
patients seen at their institution between 1992 and 1996 with
a new diagnosis of NSCLC and an FDG-PET study. The
median follow up of the surviving patients was 20.9 months.
A mean SUV was determined on the nodule on the FDG-PET
image with the maximal uptake, and the ROI used was a
circular area adjusted to include 80% of peak counts in the
nodule. Approximately 45% of patients had early-stage (I or
II) disease. The investigators found that stage, lesion size, and
SUV greater than 10 were correlated with poor prognosis
(median survival of 11.4 months versus 24.6 months for those
with SUV 10). In a multivariate analysis, the significant
association of SUV with poorer outcome persisted.
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Dhital et al.41 studied the predictive value of FDG-PET
in 77 consecutive patients with biopsy-confirmed NSCLC
referred to a single surgeon. The interpretation of this study is
limited by the lack of clear reporting of variables such as the
range of time from FDG injection to image acquisition and
the fasting glucose levels. The investigators seem to use a
SUVmean corrected for lean body mass. The investigators
reported on several different SUVs as a discriminatory factor
between patienst with poor and good prognoses. They found
a difference in 12-month survival based on a SUV cutoff of
20, although the proportion of patients surviving at this SUV
cutoff at 1 year is not clearly reported. The stage distribution
of the patients, treatments provided (presumably primarily
surgical), and corrections for other known prognostic factors
were not provided.
A Japanese study by Higashi et al.42 evaluated 57
patients with NSCLC who had been surgically treated and
had also undergone FDG-PET as part of their initial evalua-
tion. This small patient population was a pure surgical group
that specifically excluded patients with metastasis at presen-
tation and those who had received adjuvant therapy. Similar
to the Duke study, the investigators used the SUVmean for an
irregular ROI including values that were more than 90% of
the maximal uptake in the ROI on the FDG-PET image with
the most intense uptake. The median follow-up interval was
33.5 months. These investigators found a broad range of
statistically significant SUV cutoff values and used the most
significant value at an SUV cutoff of 5. There was a statis-
tically significant overall and disease-free survival advantage
for patients with SUV values below this cutoff value. Spe-
cifically, patients with stage I disease and an SUV value of
less than or equal to 5 had a 5-year expected disease-free
survival of 88%, whereas those with an SUV value greater
than 5 had an expected disease-free survival of less than or
equal to 17%. These investigators found SUV to be the most
significant independent factor affecting prognosis; it was a
better predictor than tumor size (greater than versus less than
3 cm) or stage (stage I versus stage II or III), although it
should be noted that patients with stage II or III disease
represented only approximately 20% of the total population
in this study.
A Korean study by Jeong et al.43 reviewed 73 patients
who had a diagnosis of NSCLC and had FDG-PET per-
formed. Both SUVmean and SUVmax of the primary lesion
were determined, although only the SUVmax was used for
correlation with prognosis. The authors state that surgical
staging was performed in all but two patients. They used a
SUVmax value of 7 as the cuffoff value but did not comment
on how this cutoff value was chosen. Approximately two
thirds of their patients had stage I or II disease. They found
differences in the means of SUVmax for different histological
types of NSCLC, with squamous cell carcinoma having a
TABLE 2. Technical Methods of Scanning
Author, year
# scanners
used
Fasting
time/glucose
Time from injection
to imaging
Attenuation
correction
method
Reconstruction
method
Method of SUV
determination
Sugawara et al.38 2 4 hrs
126 mg/dl
50-70 min Pre-injection
transmission scan
NR SUVlean of maximal
region of uptake
Vansteenkiste et al.39 1 6 hrs
NR
50-70 min Pre-injection
transmission scan
Filtered back
projection
SUVmax
Ahuja et al.40 2 4 hrs
NR
At least 30 min Pre-injection
transmission
NR SUVmean of ROI
containing 80% of
peak counts
Dhital et al.41 1 6 hrs
NR
NR (mean 81 min) Transmission; unclear
timing
NR SUVmean, corrected for
lean body mass
Higashi et al.42 1 4 hrs
120 mg/dl
40 min Pre-injection
transmission scan
NR SUVmean of ROI
containing 90% of
peak counts
Jeong et al.43 1 6 hrs
NRa
60 min Pre-injection
transmission scan
NR SUVmax
Downey et al.44 2 6 hrs
NR
NR Post-injection
transmission scan
Iterative SUVmax
Sasaki et al.45 1 6 hrs
150 mg/dl
60 min Post-injection
transmission scan
Iterative SUVmax
Borst et al.46 1 6 hrs
“glucose measured”
“approximately” 60 min Post-injection
transmission scan
Iterative SUVmean of ROI of all
pixels  50% of the
maximum intensity in
the ROI and SUVmax
Cerfolio et al.47 2 4 hrs
NR
60 min Pre-injection
transmission scan
for PET
Iterative SUVmax
CT exam for PET-CT
scanner
SUV, standardized uptake value; ROI, region of interest; CT, computed tomography; PET, positron emission tomography; NR, not reported.
aEuglycemic.
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higher SUVmax than adenocarcinoma, and bronchioalveolar
carcinoma having the lowest mean SUVmax; however, the
investigators did not independently analyze histology-specific
SUV. They found a statistically significant difference in
overall survival between the high- (SUVmax 7) and low-
uptake (SUVmax 7) groups. They also found differences in
survival with respect to stage (stage I to IIIA versus IIIB plus
IV) and histological subtype. However, on multivariate anal-
ysis, only stage and SUV persisted as independent prognostic
variables.
Downey et al.44 published a report on the prognostic
value of FDG-PET in 100 patients surgically treated for
NSCLC at Memorial-Sloan Kettering Cancer Center. The
authors specifically excluded patients treated with any mo-
dality other than surgery and included only patients who
underwent a R0 resection (complete resection with no resid-
TABLE 3. Summary of Studies Relating SUV to Prognosis in Patients with NSCLC
Author, year N Histology Stage Treatment Survival
Sugawara et al.38 38 Squamous
Adenocarcinoma
Large cell
32%
50%
18%
I
II
III
IV
18%
13%
55%
13%
Resection
Nonsurgical
76%
24%
Median survival (mo)a
SUV8.72
SUV8.72
NR
25.8
Vansteenkiste et al.39 125 Squamous
Adenocarcinoma
Large cell
54%
25%
21%
I
II
IIIA
IIIB
37%
15%
30%
18%
Resection
Nonsurgical
73%
27%
2-year survival
SUV7
SUV7
43%
83%
Ahuja et al.40 155 Squamous
Adenocarcinoma
Large cell
Undetermined
37%
34%
7%
23%
I or II
III
IV
45%
36%
20%
unspecified Median survival (mos.)
SUV10
SUV10
11.4
24.6
Dhital et al.41 77 Squamous
Adenocarcinoma
Large cell
Other
58%
23%
13%
5%
Not reported.
All stage IIIa or less
Presumably surgical,
specifics not
reported
Median survival (mos.)
SUV20
SUV20
6
32b
Higashi et al.42 57 Squamous
Adenocarcinoma
Large cell
BAC
Adenosquamous
14%
60%
2%
23%
2%
I
IA
IB
II
III
81%
67%
14%
4%
16%
All surgical 5-year survivalb
SUV5
SUV5
Stage I patients 5-yr
survival:
SUV5
SUV5
20%
90%
17%
88%
Jeong et al.43 73 Squamous
Adenocarcinoma
Large cell
BAC
51%
41%
3%
6%
I
II
III
IV
44%
23%
26%
7%
Resection
Non-surgical
67%
33%
Not specifically
reported.
Kaplan Meyer curves
reported.
Downey et al.44 100 Squamous
Adenocarcinoma
Large cell
Adenosquamous
Carcinoid
24%
67%
3%
2%
4%
NR
All T1-4, N0-2, M0,
treated by R0
resection
All surgical, with R0
resection
2-year survival
SUV9
SUV9
68%
96%
Sasaki et al.45 162 Squamous
Adeno or large
NOS
43%
46%
10%
I
II
IIIa
IIIb
40%
16%
13%
24%
Resection
Definitive XRT
57%
43%
2-year survival
SUV5
SUV5
94%
65%
Borst et al.46 51 Squamous
Adeno
large
NOS
33%
25%
20%
22%
I or II
III
63%
37%
All definitive XRT 2-year survival
SUV15
SUV15
60%
27%
Cerfolio et al.47 315 Squamous
Adeno
Other
54%
33%
13%
Ia
Ib
II
IIIa
IIIb
IV
19%
26%
18%
23%
5%
10%
Resection
Nonsurgical
71%
29%
Mean survival
SUV10
SUV10
3.2 yrs
1.6 yrs
aNot statistically significant.
bNot specifically reported. Estimated from Kaplan Meyer curve ROI, region of interest; NR, not yet reached at time of publication; NOS, not otherwise specified; BAC,
bronchoalveolar carcinoma; SUV, standardized uptake value. Not all percentages total 100% because of rounding.
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ual microscopic disease). The median follow-up interval for
surviving patients was 28 months. The authors used the
median size and SUVmax values to determine cutoff points for
analysis and found that both size greater than 3 cm and
SUVmax greater than 9 were statistically significantly related
to worse survival. Patients with SUVmax greater than 9 had a
2-year survival rate of 68%, whereas those with SUVmax less
than 9 had a 2-year survival rate of 96%. However, the
authors did find both size and SUVmax to be continuous
variables correlated with survival. Squamous cell carcinoma
versus adenocarcinoma was also found on univariate analysis
to be a statistically significant prognostic variable, but on
multivariate analysis, only size, SUVmax, and their interaction
significantly predicted survival. Using both a cutoff size
greater than 3cm and SUVmax greater than 9, the authors were
able to enhance their ability to determine a particularly poor
prognosis subgroup with a 3-year survival of only 47%. Few
other authors have reported the use of significant discrimina-
tors on multivariate analysis in tandem to create a more
clinically robust prognostic score.
Sasaki et al.45 reviewed 162 consecutive patients at
M.D. Anderson Cancer Center who had at least 6 months of
follow-up and had undergone FDG-PET before potentially
curative treatment for NSCLC, although only approximately
half the patients had early-stage (I or II) versus locally
advanced (stage III) disease. Surgery was the primary mo-
dality in 57% of the patients, with the rest receiving radio-
therapy as the backbone of their definitive therapy. The
median follow-up duration was only 17 months in this study.
The SUVmax was determined for both the primary lesion and
the regional lymph nodes. A SUVmax cutoff value was deter-
mined by testing several different values for statistically
significant discriminatory ability, and the investigators were
able to separate groups with good (94% 2-year overall sur-
vival) and poor (65% overall survival) survival groups (p 
0.02). They found that this significant difference in outcomes
based on SUV persisted regardless of therapeutic modality
(surgery based versus radiation based). They also found an
SUVmax cutoff value of 5 of the primary tumor predicted
differences in metastasis-free survival and loco-regional dis-
ease-controlled survival. They did not find the SUVmax of any
involved lymph nodes to predict outcome at any SUVmax
tested. On multivariate analysis, primary tumor SUVmax, age,
N stage, and performance status remained predictive of over-
all survival. Although limited by short follow-up, this study is
strengthened by its large size, which allowed this multivariate
analysis controlling for several known prognostic features, as
well as the demonstration that the prognostic value of SUV
persists regardless of treatment modality.
Borst et al.46 evaluated a series of 51 patients diagnosed
with NSCLC who were treated with definitive radiation
therapy between January 1999 and November 2001 who
underwent PET scan as part of staging evaluation. SUVmax
and SUVmean were both determined in a manually drawn ROI
around the primary lesion. They also perfomed a correction to
each SUV based on the measured pre-scan blood glucose
concentration. The authors investigated and did not find a
correlation between SUVmax and tumor volume (measured by
CT) and lymph node status. The investigators did find
SUVmax to be associated with a complete response by re-
ceiver operating characteristic analysis. Multivariate analysis
for response found SUVmax as a continuous parameter was
independently associated with response, as were stage and
performance status. A median SUVmax value of 15 was used
as the cutoff for univariate survival analysis and was associ-
ated with both disease-specific survival and overall survival.
Patients with SUVmax less than 15 had a 2-year survival of
60%, whereas those with SUVmax values greater than or equal
to 15 had a 2-year survival of only 27%. The small size of this
study and heterogeneity of stage again limit the conclusions
that can be drawn, but this study is interesting as it specifi-
cally demonstrates that SUV is associated with prognosis in
a population solely treated by a radiation-based approach,
implying that its prognostic value persists despite treatment
modality used.
The largest patient series is from Cerfolio et al.47 and
consists of 315 patients at the University of Alabama who
presented between January 2001 and June 2004 with either
biopsy-proven NSCLC or an indeterminate pulmonary nod-
ule. This study included patients with stage I to IV disease
and with a median follow-up of 26 months. FDG-PET was
performed on one of two scanners (one dedicated PET and
one PET/CT) after a 4-hour fast. Fasting glucose levels were
not described. The SUVmax within an ROI drawn around the
primary tumor was used for this study. A higher SUVmax was
found in the entire population to be independently correlated
to higher disease stage (III or IV), moderate to poor differ-
entiation on pathology, and patients who would subsequently
have a less than a complete resection. For the entire popula-
tion, an SUVmax value greater than or equal to 10 was
associated with a poor survival (mean survival 1.6 years)
compared with those with a SUVmax value less than 10 (mean
survival 3.2 years). This difference persisted on multivariate
analysis, as did survival based on stage and resection status.
The survival differences for stage Ib, II, and IIIa as predicted
by mean SUVmax in each stage also were statistically signif-
icant. Specifically, among the 82 patients with stage IB
disease, the 4-year disease-free survival was 51% for those
with SUVmax greater than the median value of 10.3 for this
group versus 92% for those with SUVmax below the median
value. The large size of this study allowed the authors to
demonstrate SUV as a correlate of prognosis, even in a
narrow early staged group. It also should be noted that a
correlation was found even though the patient population was
evaluated by two different scanners, with two different meth-
ods of attenuation correction. Although this information is
provocative, the relatively short duration of follow-up in this
patient population limits the conclusions that can be drawn.
Finally, there are data casting some doubt on the utility
of FDG-PET as an independent prognosticator for NSCLC. A
series from the University of Washington48 of 156 patients
with potentially resectable NSCLC was analyzed for corre-
lation of SUV and pathologic stage. The FDG-PET technique
was controlled to ensure acceptable fasting blood glucose
levels and standardized timing of imaging after FDG injec-
tion. The authors measured the SUVmax and also calculated a
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partial-volume-corrected SUVmax (PVC-SUVmax). They
compared the SUVmax with the well-defined stage for each
patient, and although they found a correlation between
SUVmax and T status by American Joint Committee on
Cancer tumor, node, metastasis staging, this correlation did
not persist when using the PVC-SUVmax. They specifically
note that the SUVmax was significantly different between T1
and T2, T1 and T3, and T1 and T4 tumors, but not between
any of the other T stages. The authors did not find any
correlation between N status and SUVmax or M status and
PVC-SUVmax, but they did find a correlation between
SUVmax and M status. They also demonstrated a correlation
of primary tumor size with T stage and found that the groups
of patients with and without metastasis differed significantly
with respect to size and SUVmax but not with respect to
PVC-SUVmax. The authors interpret these data to indicate
that SUVmax does not, in fact, correlate with stage when a
partial-volume correction is applied. The apparent correlation
of the uncorrected SUVmax between T1 and other T stages or
with M status occurs because SUVmax is underestimated
without this correction. Thus, the SUV is simply a surrogate
for size of the primary lesion, which is predictive for stage.
This results of study show that there is some controversy
regarding the true utility of the primary tumor SUV. In the
studies reviewed herein correlating SUV with prognosis, no
formal correction for partial-volume averaging was used. The
partial-volume corrections used by Veselle et al.35 are based
on measured recovery coefficients of spheres of known size
and radioactivity. The validity of this approach can be chal-
lenged because primary tumors are rarely perfect spheres.
However, these data only fail to demonstrate a correlation of
PVC-SUVmax and stage at presentation; in contrast, the other
studies reported in this review investigated the correlation of
SUVmax with survival and recurrence of the primary tumor.
As Veselle et al. note,35 their data do not rule out a correlation
of SUVmax and survival independent of correlation with
stage.
DISCUSSION
The currently used tumor, node, metastasis staging
system, despite its drawbacks, continues to be very useful for
predicting outcome in resected stage I-III NSCLC. FDG-PET
has the potential to identify patients with more aggressive
tumors within each stage, given the correlation between the
SUV and tumor growth rate. The challenge is to determine
whether FDG-PET can be a useful tool in identifying patients
at high risk of recurrence within each stage and, more
specifically, in resected stage I and II NSCLC.
The studies presented herein do not, however, provide
guidance regarding the use of the SUV measured by FDG-
PET to predict outcomes in routine clinical practice. None of
the reported studies were conducted prospectively. The vari-
able methods of performing the FDG-PET studies, assigning
ROIs, and determining the most appropriate SUV resulted in
a variety of SUV cutoffs used to define groups with good and
poor prognoses. It is notable that many authors found that
SUV was a continuous variable in the separation of groups
with good and poor prognoses, which suggests that a strict
binary cutoff between groups with good and poor prognoses
may not be appropriate. Moreover, all the studies suffer from
small sample size and the inclusion of patients with various
histologies and different stages of the disease with signifi-
cantly varied outcomes. To complicate matters further, a
significant number of patients had received postoperative
therapy.
We believe that the role of FDG-PET should be studied
prospectively in a homogeneous population of patients, such
as those with stage IB and II NSCLC who are scheduled to
undergo surgical resection. Determining a method for quan-
tifying FDG uptake in a way that is reproducible across
institutions will likely add to the usefulness of this approach.
To validate the hypothesis that SUV can truly discriminate
between groups with good and poor prognoses, a prospective
trial observing the differences in survival would need to be
undertaken. Future studies should take into consideration the
influence of primary tumor size (within T stage) and histol-
ogy on survival and recurrence. The increasing widespread
use of adjuvant chemotherapy after resection, although ap-
propriate, is likely to complicate the interpretation of the
studies that examine the predictive utility of FDG-PET in
NSCLC.
In conclusion, we believe that FDG-PET could be a
potentially useful tool in determining prognosis and guiding
therapy for patients with early-stage NSCLC. It is likely that
a predictive score that includes tumor size, pleural invasion,
and SUV may help to identify those at high risk of relapse
after resection of early-stage NSCLC. Such a risk stratifica-
tion approach will be useful for developing novel adjuvant
therapies for the high-risk group. Conversely, those who have
a very low risk of recurrence may be spared the side effects
of adjuvant chemotherapy.
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